*Goldstein 1966.

Methods	Allocation: randomly assigned, no further information. Blindness: double (identical capsules). Design: 2 parallel groups, single centre. Duration: no data. Analysis: no (ITT)* Country: USA.
Participants	Diagnosis: schizophrenia (clinical diagnosis). N=21. Age: range 21‐55 years. Sex: no data. Setting: hospital. History: newly addmitted. Exclusion: childhood psychoses, brain syndromes, mental deficiency, alcoholism, epilepsy, drug addiction, abnormal laboratory tests.
Interventions	1.Trifluoperazine: range 7‐20 mg/day. N=10. 2. Haloperidol: range 10‐22 mg/day. N=8.
Outcomes	Side effects. Unable to use ‐ Mental state: (IMPS ‐ no SD). Behaviour: (WBRS ‐ no SD).
Notes	* ITT not performed, dropouts each group not reported.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear